Abstract
Alcoholism is a pervasive societal problem, yet available pharmacotherapies fail to treat most sufferers. The type 1 corticotropin-releasing factor (CRF1) receptor has received much attention for its putative role in the progression to alcohol dependence, although at present its success in clinical trials has been limited. Two single-nucleotide polymorphisms in the rat Crhr1 promoter have been identified in the Marchigian substrain of Sardinian alcohol-preferring (msP) rats. Unlike other Wistar-derived alcohol-preferring lines, nondependent msP rats reduce their alcohol self-administration in response to CRF1 antagonists and show increased brain CRF1 expression. The current study tested the hypotheses that the A alleles in the Crhr1 promoter polymorphisms are: (1) unique to msP (vs. CRF1 antagonist-insensitive) alcohol-preferring lines and (2) associate with greater alcohol preference or intake. Two related polymorphisms were observed in which both loci on a given chromosome were either mutant variant (A) or wild-type (G) alleles within the distal Crhr1 promoter of 17/25 msP rats (68%), as compared to 0/23 Indiana P rats, 0/20 Sardinian alcohol-preferring rats bred at Scripps (Scr:sP) and 0/21 outbred Wistar rats. Alcohol consumption in msP rats did not differ according to the presence of Crhr1 A alleles, but greater alcohol preference (98%) was observed in A allele homozygous msP rats (AA) compared to msP rats with wild-type (GG, 91%) or heterozygous (GA, 91%) genotypes. The greater alcohol preference reflected decreased water intake, accompanied by reduced total calories consumed by AA rats. The data show that msP rats differentially possess mutant A variant alleles in the polymorphic promoter region of the Crhr1 gene that may differentially regulate consumption.
Introduction
Alcohol abuse and dependence affect about 8% of the population worldwide (), generating significant societal costs (). Despite this major public health burden, available pharmacotherapies for alcohol use disorders remain inadequate. Toward developing new therapeutic targets, rodent lines have been selectively bred for differential propensity to consume alcohol. The characterization of genetic differences in these lines may identify new molecular targets for medications development.
One target implicated in the progression and persistence of alcohol dependence is corticotropin-releasing factor (CRF), a peptide upregulated and released in the extended amygdala during alcohol withdrawal (–). Alcohol dependence confers sensitivity to CRF1 antagonists to reduce alcohol self-administration (–), similarly to binge-like alcohol consumption observed in intermittent access (–) and “Drinking in the Dark” (DID) paradigms (–). Blockade of CRF1 does not typically alter alcohol intake in nondependent rodents consuming alcohol in non-binge-like patterns (, –). Sensitization of the CRF system has been hypothesized to mediate the transition to dependence, whereby negative reinforcement (“self-medication”) putatively drives high alcohol intake in situations of CRF system hyperactivation (–). While CRF1 antagonists have so far proved largely unsuccessful to treat alcohol use disorders in human clinical trials (, ), this has been theorized to result from individual variation in clinical trial subjects’ drinking motivation, such that only a subset of the population, such as those engaging in stress-induced drinking, might respond to CRF1 antagonist treatment [reviewed in Ref. ()]. Thus understanding the role of CRF in promoting escalated alcohol intake in rodent models remains important. The presence of heightened CRF system activity in rat lines bred for high alcohol preference may recapitulate the behaviors that result from extensive alcohol exposure, and consequent recruitment of CRF circuitry, that are seen in environmental rodent models of alcohol dependence.
Several alcohol-preferring rat lines have been selectively bred from Wistar stock, including the Indiana alcohol-preferring [P ()] and Sardinian alcohol-preferring [sP ()] lines, as well as substrains derived from the sP line, including Marchigian sP [msP (, )] and Scripps sP [Scr:sP (, , )] rats. Different genetic factors may underlie each line’s excessive alcohol drinking. Studies suggest that the lines are not uniform in their CRF/CRF1 systems. For example, Scr:sP rats show elevated amygdala dialysate CRF levels relative to Sardinian non-preferring rats (), and msP rats exhibit increased CRF1 expression in the extended amygdala relative to Wistar rats (, ). In contrast, P rats show reduced CRF expression, as compared to non-preferring rats, in the amygdala and cortex (). Furthermore, despite similarly high alcohol intake, only msP rats (, , ), and not Scr:sP () or P () rats, reduce their basal levels of operant alcohol self-administration in response to CRF1 antagonists, a trait that may result from the msP rats’ elevated basal anxiety (, ).
Previously, two single-nucleotide polymorphisms (SNPs) were discovered in the distal promoter region of the CRF1 gene (Crhr1), with 85% of msP rats vs. 0% of Wistar controls possessing an A allele at both polymorphic positions (A allele) vs. the typical G allele (). The variant A allele was hypothesized to contribute to the increased CRF1 expression and CRF1 antagonist sensitivity of msP rats. However, it remains unknown whether the mutant variant A allele is unique to msP rats, relative to other alcohol-preferring lines (Scr:sP, P). Here, we tested the hypotheses that (1) the presence of the variant A allele in the Crhr1 promoter region is restricted to the CRF1 antagonist-sensitive msP line and (2) the presence of two mutant (A) alleles is associated with elevated home cage alcohol intake or preference in the msP line. Our results demonstrate that the presence of the A allele is unique to the msP strain, and that homozygous expression of the A allele (AA) was not differentially associated with elevated baseline alcohol consumption in msP rats, although the AA genotype may associate with a slight increase in alcohol preference, albeit over very high preference levels in all msP rats.
Materials and Methods
Ethics Statement
These studies were carried out in accordance with the recommendations of the European Community Council Directive for the Care and Use of Laboratory Animals and the University of Camerino Internal Ethical Committee for Laboratory Animal Protection and Use (CEAPA), or in accordance with the NIH Guide for the Care and Use of Laboratory Animals and The Scripps Research Institute Institutional Animal Care and Use Committee (IACUC). The protocols were approved by the University of Camerino CEAPA and by the Scripps Research Institute IACUC.
Animals
Subjects were adult males from two distinct sublines derived from the Sardinian preferring (sP) rats—the msP and Scr:sP rats. The breeding program of sP rats began in 1981 (University of Cagliari, Italy). Beginning with the 13th generation of sP rats, a subset of rats was provided to a separate program for selective breeding at the University of Camerino, Italy. After 20 generations of selective breeding for high alcohol preference, this distinct subline was renamed msP (). The msP rats in the present study (n = 25 for the strain comparison and n = 79 for the home cage consumption study) were from the 58th–59th generations of selective breeding. A rederivation of the msP line, to generate sublines homozygous for the G allele (GG) and homozygous for the A allele (AA), was performed as described in Ref. (). Rats from these sublines (n = 9 GG, n = 8 AA) were used for analysis of food intake when no alcohol was available. All behavioral studies, which involved only msP rats, were performed at the University of Camerino (Camerino, Italy). While these studies only include male subjects, it should be noted that sex differences in CRF1 signaling have been reported in the locus coeruleus () that might increase female responsiveness to conditions of altered CRF1 expression, although sex differences were not observed following germline Crhr1 deletion ().
In the 32nd generation of selective breeding of sP rats according to high alcohol preference at the University of Cagliari, a subset of sP rats were provided by Dr. G. L. Gessa to The Scripps Research Institute and maintained as a colony without further selective breeding. Rats from this colony were designated as Scr:sP (http://rgd.mcw.edu/rgdweb/report/strain/main.html?id=2302666). The Scr:sP subline, like the sP line from which they were derived (), show high spontaneous home cage alcohol intake (5–7 g/kg daily) and preference (>80% vs. water) and display high levels of anxiety-like behavior (, ). The Scr:sP rats in the present study (n = 20) were from the 23rd–24th generations of intra-line breeding at the Committee on the Neurobiology of Addictive Disorders of The Scripps Research Institute (La Jolla, CA, USA).
For the strain comparison, adult male outbred Wistar rats (n = 21) obtained from Charles River (Raleigh, NC, USA) were used as controls. In addition, adult male Indiana P rats (), generously provided by Dr. L. Lumeng (Indiana University School of Medicine, Indianapolis, IN, USA), also were subjects (n = 23) at The Scripps Research Institute. P rats have been bred at Indiana University School of Medicine since original establishment of the line by selective breeding from a Wistar rat colony at the Walter Reed Army Hospital (the Walter Reed Wistar rat) (42). P rats demonstrate high alcohol intake in the home cage (>5 g/kg/day) (43), yielding pharmacologically relevant blood alcohol levels (44).
Rats were housed under a 12-h reversed light cycle under constant temperature (20–22°C) and humidity (45–60%). Rats were housed three per cage in standard, wire-topped plastic cages containing sawdust bedding, with food (Camerino: 4RF18, Mucedola, Settimo Milanese, Italy; Scripps: LM-485 Diet 7012, Harlan, Madison, WI, USA) and water available ad libitum. Rats for behavioral studies received environmental enrichment prior to experimentation, at which time rats were singly housed to allow for recording of drinking and food consumption, as detailed below. At the conclusion of experiments, rats were euthanized by carbon dioxide inhalation.
Sequencing of the Crhr1 Promoter
Crhr1 promoters were sequenced in all subjects. For the strain comparison, 6 primer pairs were designed to sequence the ~2,300 bases upstream of the Crhr1 start codon (Figure 1A) and obtained from Integrated DNA Technologies (Coralville, IA, USA). The target amplicons, named P0-P5, were selected to generate an accurate, complete sequence of the proximal promoter region using slight overlap between all adjacent amplicons (Figure 1B). Primer pairs P0 and P1 were designed to overlap with the promoter sequence in which the msP Crhr1 polymorphisms were reported previously (), with each amplicon containing one of the two known SNPs, to ensure successful sequencing. Primer sequences are provided in Table 1. Tail DNA was extracted and polymerase chain reaction (PCR) was carried out with all samples (~30 ng DNA/well) run on a single 96-well plate for each primer pair with seven wells reserved as no template controls. Sequencing reactions were run in both the forward and reverse directions. ABI trace files for all high quality sequencing results (defined as Phred scores > 20 for at least 75% of the sequence) were analyzed using Mutation Surveyor. Only mutations identified in analysis of both the forward and reverse direction sequencing reactions were considered to be real mutations. This approach for complete sequencing of the 2,300 bp upstream of the Crhr1 start codon was utilized for the strain comparison study.
Figure 1
Table 1
| Amplicon | Forward primer | Reverse primer |
|---|---|---|
| P0 | TGAAATCTGCTGCTTACTGAGCCC | TGGGCAAGGAATGCGTACCTCTTA |
| P1 | AGCACTTTCCCTCCAACAACCCTA | ACTCTGTTCTCAGCACACTGGACA |
| P2 | ATCGCATGACCTACAGCAACTCCA | TCTTGAGTACCCAGAAGCACCGAA |
| P3 | TGGATCTTGTCCAGTGTGCTGAGA | AACTAAGCGTCTGTCTGTTTGGTC |
| P4 | AGCTTCAGTGTCTCAGCACATCCT | AAGTCTGGTAGCCTTCTCCCGA |
| P5 | AGAGGAGGGAGAAAGAGGAGGG | GCTTCAGAGATCCAGGTAGAGGACAT |
Crhr1 promoter primer sequences.
Once it was clear which Crhr1 promoter nucleotide positions were likely to be altered in msP rats, a more targeted genotyping approach was taken for the rats involved in the behavioral studies. Because only 2 polymorphisms were observed across all rats in the strain comparison study, PCR primers were designed to target only the expected polymorphism sites, encompassing positions −2,092 and −1,835 bp relative to ATG start of Crhr1. Primer extension assays were performed using the Sequenom iPlex Gold reagent kit (San Diego, CA, USA), and extension products analyzed by mass spectrometry using a Sequenom Mass Array system. Base calls scored as “low probability” by the Sequenom software were not used in the final analysis.
Home Cage Food and Alcohol Intake
To explore further the functional significance of the Crhr1 promoter genotype within the msP line, behavioral studies were performed in male msP rats (n = 79, weight range during experimentation 333–536 g, run in two cohorts of 32 and 47 rats, respectively). Rats were single-housed prior to the first alcohol access day to quantify home cage intake. To ascertain the relation of Crhr1 promoter genotype to home cage alcohol intake, msP rats were provided ad libitum concurrent, continuous access to 10% alcohol (0.56 kcal/ml), water and food pellets (Mucedola 4RF18, 2.6 kcal/g) until a stable baseline alcohol intake (5–7 g/kg/day) was achieved (maximum 15% daily variation, reached in 3 weeks). Alcohol was prepared as a 10% (v/v) solution in tap water, and intake of both solutions and food was measured daily at 2, 4, 8, 12, and 24 h after the onset of the dark cycle. As no time-dependent differences were observed, data are presented as 7-day means of 24-h intake. All consumption measures are normalized to body weight to account for size differences in both caloric requirement and pharmacological efficacy. To assess differences in focus on alcohol as a fluid or caloric source, data are additionally presented as percent alcohol preference [100 × 10% (v/v) alcohol intake/total fluid intake] and as percent calories derived from alcohol (100 × alcohol intake in kcal/total kcal intake), per (
Data Analysis
Strain differences in allele frequency were determined by Pearson’s chi square analysis. Alcohol intake, water intake and alcohol preference data were not normally distributed, possibly due to floor and ceiling effects, respectively, and thus were analyzed by ANOVA on ranks rather than ANOVA on raw values, with post hoc comparisons performed using Dunn’s method. Body weight, food intake and caloric intake data were found to conform to normal distributions, and thus were analyzed by one-way ANOVA, with post hoc comparisons via Tukey’s test. SigmaPlot 13.0 and Systat 13 (Chicago, IL, USA) software were used to perform the statistical analyses.
Results
Crhr1 Promoter SNP Prevalence in Wistar-Derived Alcohol-Preferring Rat Strains
Previously, two G-to-A base pair substitutions were reported 2,097 and 1,836 bases upstream from the start codon in the Crhr1 promoter region of most (85%) msP rats (
Table 2
| Strain | Subjects | Double SNP expressing | Prevalence (%) |
|---|---|---|---|
| Wistar | 21 | 0 | 0.0 |
| Indiana P | 23 | 0a | 0.0 |
| Scr:sP | 20 | 0 | 0.0 |
| msP | 25 | 17 | 68.0*** |
Prevalence of Crhr1 promoter polymorphisms in normal and alcohol-preferring rat strains.
***p < 0.001 vs. all other groups.
aOne Indiana P rat (4.3%) displayed one but not both SNPs.
Relation of the Crhr1 Promoter SNPs to Alcohol Intake and Preference
As the recently reported analysis of brain region-specific Crhr1 expression was performed in rederived lines of GG and AA msP rats (
Figure 2

Marchigian substrain of Sardinian alcohol-preferring (msP) rats carrying the Crhr1 promoter polymorphisms on both alleles show altered alcohol preference, water intake and calories consumed. Home cage fluid intake and preference were determined for msP rats with known Crhr1 promoter genotypes consuming 10% alcohol under a two-bottle choice paradigm. Genotype-specific effects were assessed for (A) alcohol intake, (B) alcohol preference [(alcohol consumed)/(total fluid intake)], (C) water intake, (D) total fluid intake, (E) percent calories obtained from alcohol [(alcohol calories consumed)/(total caloric intake)], and (F) total calorie intake. Data are expressed as mean ± SEM daily measurements averaged across 7 days of stable intake. Overlaid on histograms are individual subjects’ data points to demonstrate the variability among subjects in each group. *p < 0.05 vs. GG and GA, $p < 0.05 vs. GA. n = 11 AA, 27 GA, 41 GG.
AA rats also showed nonsignificant trends to eat less food (one-way ANOVA, F2,76 = 2.65, p = 0.08), yet weigh more (F2,76 = 2.75, p = 0.07), as shown in Table 3. Because alcohol provides a source of calories, the increased preference and reduced food intake suggested a possible shift toward obtaining calories from alcohol. To investigate this possibility, the percent of total calories obtained from alcohol was calculated. Crhr1 promoter genotype did not significantly alter the use of alcohol as a calorie source (Figure 2E, one-way ANOVA, F2,76 = 1.39, p = 0.26), although genotype did significantly impact total caloric intake (Figure 2F, one-way ANOVA, F2,76 = 4.09, p < 0.05), with AA rats consuming significantly fewer calories than GA, but not GG, rats. These data suggest a role for Crhr1 promoter genotype in regulating caloric intake, but the possibility remained that alcohol availability might alter food intake. To assess Crhr1 promoter genotype effects on food intake under baseline conditions, when alcohol was not available, food consumption was measured in AA and GG rats from the rederived msP lines (
Table 3
| Promoter genotype | Food (kcal) | Weight (g) |
|---|---|---|
| 10% alcohol available concurrently | ||
| AA | 117.8 ± 2.4 | 452.7 ± 6.5 |
| GA | 128.4 ± 2.7 | 421.3 ± 6.8 |
| GG | 124.8 ± 2.1 | 433.4 ± 6.6 |
| No alcohol available | ||
| AA | 57.3 ± 1.7 | 415.4 ± 8.1 |
| GG | 54.3 ± 1.8 | 417.7 ± 8.0 |
Food intake and body weight of msP rats with home cage two-bottle choice access to 10% alcohol.
Food intake and body weight expressed as mean ± SEM.
Discussion
The present data demonstrate that the A allele polymorphisms in the Crhr1 promoter region are specific to msP rats and likely play a minor role in promoting alcohol drinking under unstressed conditions. The two previously described (
Crhr1 Polymorphisms and the Regulation of CRF1 Expression
Hansson et al. originally reported 2 G-to-A substitutions in the promoter region of Crhr1 of msP rats on one or both gene loci in a majority (85%) of msP rats (
In addition to the reduced frequency of the dual polymorphism in the current msP cohort, slight differences in the locations of both SNPs were identified in the genetic analysis, with one located 1,835 bp (rather than 1,836 bp) upstream of the receptor start codon, and the second SNP at 2,092 bp (rather than 2,097 bp) upstream. This discrepancy in position may reflect modification of the genome sequence since the original identification of the polymorphisms. Both loci lie well outside the proximal core promoter region (47), which could explain the apparent lack of involvement of the variant alleles in basal amygdala Crhr1 expression (
One mechanism by which stress may alter CRF1 function, via altered receptor expression, involves changes in distal promoter methylation status. The Crhr1 promoter region lies within a CpG island, and behavioral experiences that alter anxiety-like behavior have been shown to increase methylation on one CpG site located 1,348 bases upstream of the Crhr1 translation start in the amygdala (52). Recently, stress-related changes in gene methylation status and expression of another receptor (Oprl1) were shown in msP rats using a stress paradigm that increased msP rats’ alcohol consumption (53), indicating that stressors that exacerbate alcohol intake in msPs might accomplish this via altered methylation, and thereby expression, of specific gene targets. Since AA msP rats are anticipated to be more susceptible to stress-induced elevations in drinking based on yohimbine exacerbation of operant alcohol self-administration (
CRF1 Regulation of Alcohol Intake
Increased activation of the CRF system is evident in the progression to substance dependence, including for alcohol [reviewed in Ref. (54)]. Pharmacological and genetic studies specifically implicate activation of extended amygdala CRF1 receptors in mediating the excessive alcohol self-administration resulting from chronic intermittent exposure (
Human studies support the involvement of CRF/CRF1 in alcohol dependence (
Crhr1 Promoter Genotype and Caloric Intake
Expression of the dual polymorphism in the Crhr1 promoter was associated with increased alcohol preference, although preference levels were near ceiling in all genotypes and differences appear to result from decreased water intake rather than significantly increased alcohol intake per se. However, msP AA rats also consumed significantly less total calories than rats of the GA genotype, and tended to consume less food than both GG and GA genotype rats. While these results initially suggested a possible shift in calorie focus toward alcohol for AA msP rats—as observed in human alcoholics who transition toward consuming half their daily calories in alcohol (78, 79)—direct assessment of this possibility showed no significant genotype effects on percent of calories obtained from alcohol. Instead, these results suggest that Crhr1 promoter genotype plays a more general role in regulating caloric intake that may not be specific to alcohol. Both CRF1 agonist (80) and antagonist (
Conclusion
Here, we show that two joint variants in the distal promoter region of Crhr1 are restricted to the msP line, relative to other alcohol-preferring strains, and associate with increased alcohol preference, although all rats display extremely high preference, as well as decreased water intake and reduced total caloric consumption. In light of the growing body of literature demonstrating associations between polymorphisms in human CRHR1 and CRFBP and comorbid stress/anxiety and AUD, the present data support a continued focus on CRF1 as a therapeutic target not for the global AUD population, but rather for a subset of AUD individuals, particularly those with stress-related comorbidities. A pharmacogenomic approach that accounts for CRF system polymorphisms may have particular utility for the treatment of alcohol use disorders.
Statements
Ethics statement
These studies were carried out in accordance with the recommendations of the European Community Council Directive for the Care and Use of Laboratory Animals and the University of Camerino Internal Ethical Committee for Laboratory Animal Protection and Use (CEAPA), or in accordance with the NIH Guide for the Care and Use of Laboratory Animals and The Scripps Research Institute Institutional Animal Care and Use Committee (IACUC). The protocols were approved by the University of Camerino CEAPA and by the Scripps Research Institute IACUC.
Author contributions
ML analyzed data and wrote the manuscript; JW designed experiments, collected and analyzed data, and edited the manuscript; LA collected data and edited the manuscript; VS designed experiments, collected data, and edited the manuscript; RC designed experiments and edited the manuscript; GK designed experiments and edited the manuscript; EZ designed experiments and wrote the manuscript.
Funding
Research was financially supported by the Pearson Center for Alcoholism and Addiction Research, by National Institutes of Health grants AA006420 (GK and EZ), AA008459 (GK), AA018914 (ML), and AA021802 (ML) from the National Institute on Alcohol Abuse and Alcoholism and DK026741 (GK) from the National Institute of Diabetes and Digestive and Kidney Diseases. Additional financial support was provided by Dr. Marisa Roberto through NIH grants AA006420 and AA017447 from the National Institute on Alcohol Abuse and Alcoholism. Generation, breeding and provision of P rats were possible thanks to NIH grants AA015512 and AA007611 (animal production core) from the National Institute on Alcohol Abuse and Alcoholism to Dr. Lawrence Lumeng. A portion of this work was also supported by the Intramural Research Programs of the National Institute on Drug Abuse. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Acknowledgments
The authors thank S. Whitney Barnes for technical assistance, Michael Arends for proofreading the manuscript, and Dr. Marisa Roberto for financial assistance. The authors also thank Dr. Lawrence Lumeng for providing the P rats to The Scripps Research Institute and Dr. Nicholas Gilpin for providing samples from the P rats for genotyping. This is publication number 21809 from The Scripps Research Institute.
Conflict of interest
GK and EZ are inventors on a patent for the composition and use of non-peptide CRF1 receptor antagonists (US20100249138). All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer DF and handling editor declared their shared affiliation.
References
1
World Health Organization. Global Status Report on Alcohol and Health. Geneva, Switzerland: World Health Organization (2014).
2
RehmJMathersCPopovaSThavorncharoensapMTeerawattananonYPatraJ. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet (2009) 373:2223–33.10.1016/S0140-6736(09)60746-7
3
ZorrillaEPValdezGRWeissF. Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (2001) 158:374–81.10.1007/s002130100773
4
OliveMFKoenigHNNanniniMAHodgeCW. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav (2002) 72:213–20.10.1016/S0091-3057(01)00748-1
5
RobertoMCruzMTGilpinNWSabinoVSchweitzerPBajoMet alCorticotropin releasing factor-induced amygdala gamma-aminobutyric acid release plays a key role in alcohol dependence. Biol Psychiatry (2010) 67:831–9.10.1016/j.biopsych.2009.11.007
6
Merlo PichELorangMYeganehMRodriguez de FonsecaFRaberJKoobGFet alIncrease of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci (1995) 15:5439–47.
7
FunkCKZorrillaEPLeeMJRiceKCKoobGF. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry (2007) 61:78–86.10.1016/j.biopsych.2006.03.063
8
ChuKKoobGFColeMZorrillaEPRobertsAJ. Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol Biochem Behav (2007) 86:813–21.10.1016/j.pbb.2007.03.009
9
SabinoVCottonePKoobGFSteardoLLeeMJRiceKCet alDissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology (2006) 189:175–86.10.1007/s00213-006-0546-5
10
CippitelliADamadzicRSingleyEThorsellACiccocioppoREskayRLet alPharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats. Pharmacol Biochem Behav (2012) 100:522–9.10.1016/j.pbb.2011.10.016
11
HwaLSDeboldJFMiczekKA. Alcohol in excess: CRF(1) receptors in the rat and mouse VTA and DRN. Psychopharmacology (2013) 225:313–27.10.1007/s00213-012-2820-z
12
HwaLSHollyENDeBoldJFMiczekKA. Social stress-escalated intermittent alcohol drinking: modulation by CRF-R1 in the ventral tegmental area and accumbal dopamine in mice. Psychopharmacology (2016) 233:681–90.10.1007/s00213-015-4144-2
13
SimmsJANielsenCKLiRBartlettSE. Intermittent access ethanol consumption dysregulates CRF function in the hypothalamus and is attenuated by the CRF-R1 antagonist, CP-376395. Addict Biol (2014) 19:606–11.10.1111/adb.12024
14
SpartaDRSparrowAMLoweryEGFeeJRKnappDJThieleTE. Blockade of the corticotropin releasing factor type 1 receptor attenuates elevated ethanol drinking associated with drinking in the dark procedures. Alcohol Clin Exp Res (2008) 32:259–65.10.1111/j.1530-0277.2007.00575.x
15
Lowery-GiontaEGNavarroMLiCPleilKERinkerJACoxBRet alCorticotropin releasing factor signaling in the central amygdala is recruited during binge-like ethanol consumption in C57BL/6J mice. J Neurosci (2012) 32:3405–13.10.1523/JNEUROSCI.6256-11.2012
16
KaurSLiJStenzel-PooreMPRyabininAE. Corticotropin-releasing factor acting on corticotropin-releasing factor receptor type 1 is critical for binge alcohol drinking in mice. Alcohol Clin Exp Res (2012) 36:369–76.10.1111/j.1530-0277.2011.01610.x
17
GiardinoWJRyabininAE. CRF1 receptor signaling regulates food and fluid intake in the drinking-in-the-dark model of binge alcohol consumption. Alcohol Clin Exp Res (2013) 37:1161–70.10.1111/acer.12076
18
HeiligMKoobGF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci (2007) 30:399–406.10.1016/j.tins.2007.06.006
19
ZorrillaEPLogripMLKoobGF. Corticotropin releasing factor: a key role in the neurobiology of addiction. Front Neuroendocrinol (2014) 35:234–44.10.1016/j.yfrne.2014.01.001
20
KoobGF. Neurocircuitry of alcohol addiction: synthesis from animal models. Handb Clin Neurol (2014) 125:33–54.10.1016/B978-0-444-62619-6.00003-3
21
SchwandtMLCortesCRKwakoLEGeorgeDTMomenanRSinhaRet alThe CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology (2016) 41:2818–29.10.1038/npp.2016.61
22
KwakoLESpagnoloPASchwandtMLThorsellAGeorgeDTMomenanRet alThe corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology (2015) 40:1053–63.10.1038/npp.2014.306
23
SpierlingSRZorrillaEP. Don’t stress about CRF: assessing the translational failures of CRF1antagonists. Psychopharmacology (2017) 234:1467–81.10.1007/s00213-017-4556-2
24
LiTKLumengLDoolittleDPCarrLG. Molecular associations of alcohol-seeking behavior in rat lines selectively bred for high and low voluntary ethanol drinking. Alcohol Alcohol Suppl (1991) 1:121–4.
25
ColomboGAgabioRLobinaCRealiRZocchiAFaddaFet alSardinian alcohol-preferring rats: a genetic animal model of anxiety. Physiol Behav (1995) 57:1181–5.10.1016/0031-9384(94)00382-F
26
CiccocioppoRPanockaIPolidoriCFroldiRAngelettiSMassiM. Mechanism of action for reduction of ethanol intake in rats by the tachykinin NK-3 receptor agonist aminosenktide. Pharmacol Biochem Behav (1998) 61:459–64.10.1016/S0091-3057(98)00090-2
27
CiccocioppoREconomidouDCippitelliACucculelliMUbaldiMSoverchiaLet alGenetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism. Addict Biol (2006) 11:339–55.10.1111/j.1369-1600.2006.00032.x
28
FonarevaISpanglerECannellaNSabinoVCottonePCiccocioppoRet alIncreased perioculomotor urocortin 1 immunoreactivity in genetically selected alcohol preferring rats. Alcohol Clin Exp Res (2009) 33:1956–65.10.1111/j.1530-0277.2009.01033.x
29
LogripMLVendruscoloLFSchlosburgJEKoobGFZorrillaEP. Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. Neuropsychopharmacology (2014) 39:1722–31.10.1038/npp.2014.20
30
RichterRMZorrillaEPBassoAMKoobGFWeissF. Altered amygdalar CRF release and increased anxiety-like behavior in Sardinian alcohol-preferring rats: a microdialysis and behavioral study. Alcohol Clin Exp Res (2000) 24:1765–72.10.1111/j.1530-0277.2000.tb01979.x
31
HanssonACCippitelliASommerWHFedeliABjorkKSoverchiaLet alVariation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci U S A (2006) 103:15236–41.10.1073/pnas.0604419103
32
CippitelliAAyanwuyiLOBarbierEDomiELerma-CabreraJMCarvajalFet alPolymorphism in the corticotropin-releasing factor receptor 1 (CRF1-R) gene plays a role in shaping the high anxious phenotype of Marchigian Sardinian alcohol-preferring (msP) rats. Psychopharmacology (2015) 232:1083–93.10.1007/s00213-014-3743-7
33
EhlersCLChaplinRIWallTLLumengLLiTKOwensMJet alCorticotropin releasing factor (CRF): studies in alcohol preferring and non-preferring rats. Psychopharmacology (1992) 106:359–64.10.1007/BF02245418
34
GehlertDRCippitelliAThorsellALeADHipskindPAHamdouchiCet al3-(4-chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo [1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci (2007) 27:2718–26.10.1523/JNEUROSCI.4985-06.2007
35
AyanwuyiLOCarvajalFLerma-CabreraJMDomiEBjorkKUbaldiMet alRole of a genetic polymorphism in the corticotropin-releasing factor receptor 1 gene in alcohol drinking and seeking behaviors of Marchigian Sardinian alcohol-preferring rats. Front Psychiatry (2013) 4:23.10.3389/fpsyt.2013.00023
36
GilpinNWRichardsonHNKoobGF. Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol Clin Exp Res (2008) 32:1535–42.10.1111/j.1530-0277.2008.00745.x
37
BangasserDACurtisAReyesBABetheaTTParastatidisIIschiropoulosHet alSex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol Psychiatry (2010) 15(877):896–904.10.1038/mp.2010.66
38
TimplPSpanagelRSillaberIKresseAReulJMStallaGKet alImpaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet (1998) 19:162–6.10.1038/520
39
ColomboGLobinaCCaraiMAGessaGL. Phenotypic characterization of genetically selected Sardinian alcohol-preferring (sP) and -non-preferring (sNP) rats. Addict Biol (2006) 11:324–38.10.1111/j.1369-1600.2006.00031.x
40
SabinoVCottonePSteardoLSchmidhammerHZorrillaEP. 14-methoxymetopon, a highly potent mu opioid agonist, biphasically affects ethanol intake in Sardinian alcohol-preferring rats. Psychopharmacology (2007) 192:537–46.10.1007/s00213-007-0746-7
41
BellRLRoddZALumengLMurphyJMMcBrideWJ. The alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict Biol (2006) 11:270–88.10.1111/j.1369-1600.2005.00029.x
42
LumengLHawkinsTDLiTK. New strains of rats with alcohol preference and non-preference. In: ThurmanRGWilliamsonJRDrottHChanceB, editors. Alcohol and Aldehyde Metabolizing Systems. New York: Academic Press (1977). p. 537–44.
43
LiTKLumengLMcBrideWJMurphyJM. Rodent lines selected for factors affecting alcohol consumption. Alcohol Alcohol Suppl (1987) 1:91–6.
44
MurphyJMGattoGJWallerMBMcBrideWJLumengLLiTK. Effects of scheduled access on ethanol intake by the alcohol-preferring (P) line of rats. Alcohol (1986) 3:331–6.10.1016/0741-8329(86)90010-8
45
GiardinoWJRodriguezEDSmithMLFordMMGaliliDMitchellSHet alControl of chronic excessive alcohol drinking by genetic manipulation of the Edinger-Westphal nucleus urocortin-1 neuropeptide system. Transl Psychiatry (2017) 7:e1021.10.1038/tp.2016.293
46
NatividadLABuczynskiMWHermanMAKirsonDOleataCSIrimiaCet alConstitutive increases in amygdalar corticotropin-releasing factor and fatty acid amide hydrolase drive an anxious phenotype. Biol Psychiatry (2017) 82:500–10.10.1016/j.biopsych.2017.01.005
47
RiethovenJJ. Regulatory regions in DNA: promoters, enhancers, silencers, and insulators. Methods Mol Biol (2010) 674:33–42.10.1007/978-1-60761-854-6_3
48
PaakinahoVMakkonenHJaaskelainenTPalvimoJJ. Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol Endocrinol (2010) 24:511–25.10.1210/me.2009-0443
49
KrivegaIDeanA. Enhancer and promoter interactions-long distance calls. Curr Opin Genet Dev (2012) 22:79–85.10.1016/j.gde.2011.11.001
50
CorradinOScacheriPC. Enhancer variants: evaluating functions in common disease. Genome Med (2014) 6:85.10.1186/s13073-014-0085-3
51
NolisIKMcKayDJMantouvalouELomvardasSMerikaMThanosD. Transcription factors mediate long-range enhancer-promoter interactions. Proc Natl Acad Sci U S A (2009) 106:20222–7.10.1073/pnas.0902454106
52
SotnikovSVMarktPOMalikVChekmarevaNYNaikRRSahAet alBidirectional rescue of extreme genetic predispositions to anxiety: impact of CRH receptor 1 as epigenetic plasticity gene in the amygdala. Transl Psychiatry (2014) 4:e359.10.1038/tp.2013.127
53
RuggeriBMacareCStopponiSJiaTCarvalhoFMRobertGet alMethylation of OPRL1 mediates the effect of psychosocial stress on binge drinking in adolescents. J Child Psychol Psychiatry (2017).10.1111/jcpp.12843
54
LogripMLKoobGFZorrillaEP. Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention. CNS Drugs (2011) 25:271–87.10.2165/11587790-000000000-00000
55
FunkCKO’DellLECrawfordEFKoobGF. Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci (2006) 26:11324–32.10.1523/JNEUROSCI.3096-06.2006
56
SommerWHRimondiniRHanssonACHipskindPAGehlertDRBarrCSet alUpregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry (2008) 63:139–45.10.1016/j.biopsych.2007.01.010
57
RobertoMBajoMCrawfordEMadambaSGSigginsGR. Chronic ethanol exposure and protracted abstinence alter NMDA receptors in central amygdala. Neuropsychopharmacology (2006) 31:988–96.10.1038/sj.npp.1300840
58
RobertoMMadambaSGStoufferDGParsonsLHSigginsGR. Increased GABA release in the central amygdala of ethanol-dependent rats. J Neurosci (2004) 24:10159–66.10.1523/JNEUROSCI.3004-04.2004
59
HermanMAVarodayanFPOleataCSLuuGKirsonDHeiligMet alGlutamatergic transmission in the central nucleus of the amygdala is selectively altered in Marchigian Sardinian alcohol-preferring rats: alcohol and CRF effects. Neuropharmacology (2016) 102:21–31.10.1016/j.neuropharm.2015.10.027
60
HermanMAKallupiMLuuGOleataCSHeiligMKoobGFet alEnhanced GABAergic transmission in the central nucleus of the amygdala of genetically selected Marchigian Sardinian rats: alcohol and CRF effects. Neuropharmacology (2013) 67:337–48.10.1016/j.neuropharm.2012.11.026
61
ValdezGRRobertsAJChanKDavisHBrennanMZorrillaEPet alIncreased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol Clin Exp Res (2002) 26:1494–501.10.1111/j.1530-0277.2002.tb02448.x
62
RichardsonHNZhaoYFeketeEMFunkCKWirschingPJandaKDet alMPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav (2008) 88:497–510.10.1016/j.pbb.2007.10.008
63
HwaLSNathansonAJShimamotoATayehJKWilensARHollyENet alAggression and increased glutamate in the mPFC during withdrawal from intermittent alcohol in outbred mice. Psychopharmacology (2015) 232:2889–902.10.1007/s00213-015-3925-y
64
TurekVFTsivkovskaiaNOHyytiaPHardingSLeADRyabininAE. Urocortin 1 expression in five pairs of rat lines selectively bred for differences in alcohol drinking. Psychopharmacology (2005) 181:511–7.10.1007/s00213-005-0011-x
65
SabinoVCottonePBlasioAIyerMRSteardoLRiceKCet alActivation of sigma-receptors induces binge-like drinking in Sardinian alcohol-preferring rats. Neuropsychopharmacology (2011) 36:1207–18.10.1038/npp.2011.5
66
ZorrillaEPHeiligMde WitHShahamY. Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend (2013) 128:175–86.10.1016/j.drugalcdep.2012.12.017
67
AdinoffBAntonRLinnoilaMGuidottiANemeroffCBBissetteG. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmacology (1996) 15:288–95.10.1016/0893-133X(95)00212-V
68
TreutleinJKisslingCFrankJWiemannSDongLDepnerMet alGenetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry (2006) 11:594–602.10.1038/sj.mp.4001813
69
ChenACManzNTangYRangaswamyMAlmasyLKupermanSet alSingle-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene (CRHR1) are associated with quantitative trait of event-related potential and alcohol dependence. Alcohol Clin Exp Res (2010) 34:988–96.10.1111/j.1530-0277.2010.01173.x
70
BlomeyerDTreutleinJEsserGSchmidtMHSchumannGLauchtM. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry (2008) 63:146–51.10.1016/j.biopsych.2007.04.026
71
MolanderAVengelieneVHeiligMWurstWDeussingJMSpanagelR. Brain-specific inactivation of the Crhr1 gene inhibits post-dependent and stress-induced alcohol intake, but does not affect relapse-like drinking. Neuropsychopharmacology (2012) 37:1047–56.10.1038/npp.2011.297
72
EnochMAShenPHDucciFYuanQLiuJWhiteKVet alCommon genetic origins for EEG, alcoholism and anxiety: the role of CRH-BP. PLoS One (2008) 3:e3620.10.1371/journal.pone.0003620
73
BegleiterHPlatzA. The effects of alcohol on the central nervous system in humans. In: KissinBBegleiterH, editors. The Biology of Alcoholism, Volume 2, Physiology and Behavior. New York: Plenum Publishing Corporation (1972). p. 293–343.
74
EnochMAWhiteKVHarrisCRRobinRWRossJRohrbaughJWet alAssociation of low-voltage alpha EEG with a subtype of alcohol use disorders. Alcohol Clin Exp Res (1999) 23:1312–9.10.1111/j.1530-0277.1999.tb04352.x
75
RayLA. Stress-induced and cue-induced craving for alcohol in heavy drinkers: preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes. Alcohol Clin Exp Res (2011) 35:166–74.10.1111/j.1530-0277.2010.01333.x
76
Haass-KofflerCLHenryATMelkusGSimmsJANaemmuddinMNielsenCKet alDefining the role of corticotropin releasing factor binding protein in alcohol consumption. Transl Psychiatry (2016) 6:e953.10.1038/tp.2016.208
77
RibbeKAckermannVSchwitullaJBegemannMPapiolSGrubeSet alPrediction of the risk of comorbid alcoholism in schizophrenia by interaction of common genetic variants in the corticotropin-releasing factor system. Arch Gen Psychiatry (2011) 68:1247–56.10.1001/archgenpsychiatry.2011.100
78
MezeyEFaillaceLA. Metabolic impairment and recovery time in acute ethanol intoxication. J Nerv Ment Dis (1971) 153:445–52.10.1097/00005053-197112000-00007
79
MezeyE. Alcoholic liver disease: roles of alcohol and malnutrition. Am J Clin Nutr (1980) 33:2709–18.10.1093/ajcn/33.12.2709
80
ZorrillaEPReinhardtLEValdezGRInoueKRivierJEValeWWet alHuman urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity. J Pharmacol Exp Ther (2004) 310:1027–34.10.1124/jpet.104.068676
Summary
Keywords
alcohol, ethanol, corticotropin-releasing factor, corticotropin-releasing hormone, promoter, single-nucleotide polymorphism, genetic vulnerability, selective breeding
Citation
Logrip ML, Walker JR, Ayanwuyi LO, Sabino V, Ciccocioppo R, Koob GF and Zorrilla EP (2018) Evaluation of Alcohol Preference and Drinking in msP Rats Bearing a Crhr1 Promoter Polymorphism. Front. Psychiatry 9:28. doi: 10.3389/fpsyt.2018.00028
Received
19 August 2017
Accepted
23 January 2018
Published
15 February 2018
Volume
9 - 2018
Edited by
Andrey E. Ryabinin, Oregon Health & Science University, United States
Reviewed by
William J. Giardino, Stanford University, United States; Tamas Kozicz, Radboud University Nijmegen, Netherlands; Deborah Ann Finn, Oregon Health & Science University, United States
Updates

Check for updates
Copyright
© 2018 Logrip, Walker, Ayanwuyi, Sabino, Ciccocioppo, Koob and Zorrilla.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eric P. Zorrilla, ezorrilla@scripps.edu
Specialty section: This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.